Brenda Cooperstone
Directeur/Membre du Conseil chez SENTI BIOSCIENCES, INC.
Fortune : - $ au 30/06/2024
Profil
Brenda Cooperstone is currently the Director at Senti Sub I, Inc., the Independent Director at Lexeo Therapeutics, Inc., the Independent Director at Senti Biosciences, Inc., and the Independent Director at Gandeeva Therapeutics, Inc. Previously, she worked at Pfizer Inc. as the Chief Development Officer & Senior Vice President from 2017 to 2022.
Dr. Cooperstone holds a doctorate degree from McGill University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SENTI BIOSCIENCES, INC.
-.--% | 10/07/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
LEXEO THERAPEUTICS, INC.
-.--% | 25/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Brenda Cooperstone
| Sociétés | Poste | Début |
|---|---|---|
| SENTI BIOSCIENCES, INC. | Directeur/Membre du Conseil | 01/10/2019 |
| LEXEO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/08/2023 |
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Directeur/Membre du Conseil | 01/10/2019 |
Gandeeva Therapeutics, Inc.
 Gandeeva Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Gandeeva Therapeutics, Inc. is a Canadian company that specializes in drug discovery using a unique approach to develop precision medicines. The company is based in Vancouver, Canada and was founded by Sriram Subramaniam, who has been the CEO since incorporation. The company's focus is on understanding the language by which proteins communicate in vivo, which is fundamental to deciphering biology. The company's discovery process involves identifying the optimal protein-protein interactions and altering protein structures to develop drugs that can treat various diseases. | Directeur/Membre du Conseil | 23/01/2023 |
Anciens postes connus de Brenda Cooperstone
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/12/2022 |
Formation de Brenda Cooperstone
| McGill University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| LEXEO THERAPEUTICS, INC. | Health Technology |
| SENTI BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
Gandeeva Therapeutics, Inc.
Gandeeva Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Gandeeva Therapeutics, Inc. is a Canadian company that specializes in drug discovery using a unique approach to develop precision medicines. The company is based in Vancouver, Canada and was founded by Sriram Subramaniam, who has been the CEO since incorporation. The company's focus is on understanding the language by which proteins communicate in vivo, which is fundamental to deciphering biology. The company's discovery process involves identifying the optimal protein-protein interactions and altering protein structures to develop drugs that can treat various diseases. | Commercial Services |
